Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...

Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...

The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

WASHINGTON (Reuters) - The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' ...

Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...

The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...

The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...

Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...

Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

The Federal Trade Commission announced it has sued to block GTCR BC Holdings’ acquisition of Surmodics (SRDX), alleging that the deal, which ...